COVID-19 ringing in new mobile age

COVID-19 ringing in new mobile age
View As Webpage

NTT Data
 
HIMSS
 
 

Monday, July 13, 2020

 
 
Chart of M&A covered by MobiHealthNews
 

UnitedHealth Group offering Dexcom G6 CGMs, Fitbit trackers, virtual coaching to 230,000 Type 2 members >>

 

BY DAVE MUOIO

UnitedHealth Group announced plans this morning to distribute a device-driven diabetes management model to 230,000 employer-sponsored members with Type 2 diabetes at no additional cost.

The pilot program, called Level2 by UnitedHealthcare, provides members with a Dexcom G6 continuous glucose monitor (CGM) that connects to their smartphone, a Fitbit activity tracker, personalized coaching and virtual specialist consultations. The latter two services can be delivered via voice, text or video chat, and aim to develop care plans and assist with medication management.

Level2 will also incentivize the members it enrolls to continue healthy behaviors with rewards such as gift cards or cash. The stipulations for these will vary between states and plans, UnitedHealth said, but could include step goals, wearing the CGM, meeting with a virtual coach, reporting behaviors in the Level2 app or simply enrolling.

Members in 27 states and Washington D.C. are now eligible for the program, and it will be made available to "select employers with self-funded plans" later in 2020. The payer also noted that the Level2 model could see deployment among members with other chronic conditions down the road.

WHAT'S THE IMPACT?

Level2's tech-assisted approach to chronic care was tested in a pilot study of more than 790 UnitedHealthcare members. According to the company, "certain" participants recorded clinical A1C reduction within 90 days, and those with a starting A1C over 8% achieved reductions greater than 1% on average.

The company's announcement also highlighted the Level2 program's ability to spot sudden blood-sugar changes that could signal infection with COVID-19, and noted worsened COVID-19 outcomes among Type 2 diabetes patients with uncontrolled blood sugar.

“With diabetes rates on the rise and people with the condition at higher risk for complications if they get COVID-19, UnitedHealth Group’s expansion of Level2 is using technology to help more Americans stabilize their blood sugar and, for some, even achieve diabetes remission,” Dr. Amy Meister, CEO of Level2, told MobiHealthNews in an email statement. “Through Level2, the combination of wearable technology, coaching and personalized recommendations is making a meaningful difference for enrolled members, helping participants gain real-time insights to drive long-term, sustainable lifestyle changes and achieve improved well-being.”  

THE LARGER TREND

A number of diabetes-tech vendors have highlighted the role CGMs and accompanying support programs can play in managing the condition, both in terms of outcomes and costs. But UnitedHealth Group's new model also brings to mind the various wellness programs employed by the payer and others, which similarly use devices like Fitbits and Apple Watches to track healthy behaviors and award monetary incentives.

Young adult woman lying on a bed with a smartphone
 

Swedish pharma company Orexo rolls out digital therapeutics for depression, alcohol use disorder >>

 

BY LAURA LOVETT

Swedish pharma company Orexo is jumping into the American digital-therapeutics game with the announcement of two new products, deprexis for treating depression symptoms and vorvida, a treatment for problematic alcohol use. 

The new treatments are coming to the US market thanks to relaxed FDA regulations surrounding digital health products for psychiatric disorders, which was enacted as a result of the coronavirus pandemic.  

The company said that, with the FDA’s temporary policy change, it is also fast-tracking the development of its digital therapeutic of opioid use disorder, dubbed OXD01, for Q4 2020. 

Both of the digital therapeutics employ artificial intelligence systems in order to deliver the treatment. 

WHY IT MATTERS

Depression and alcohol use disorder are both common conditions. The World Health Organization, reports that approximately 265 million people globally are living with depression, and that the condition is a leading cause of disability in the world.  

Alcohol use disorder also impacts many around the world. In fact, in the US 14.4 million adults in the use experience the disorder. 

While the COVID-19 pandemic has created barriers to in-person care, many are pitching technology as a way to help reach individuals in their home. 

“Due to the COVID-19 pandemic, the need for clinically validated digital therapies is unprecedented. This pressing need, combined with the FDA's measures to expand availability of digital therapies for psychiatric disorders, have accelerated launch plans for Orexo's digital offering,” Nikolaj Sørensen, president and CEO of Orexo AB, said in a statement. “This aligns with our strategy to increase our product offering and to further leverage our commercial US infrastructure. Orexo has a profitable and well-funded pharmaceutical business enabling the investment required to capitalize on the current digital therapies opportunity, drive longer term growth and address patient need."

THE LARGER TREND 

Digital therapeutics is a growing industry inside the world of healthcare. One of the biggest names in the space is Pear Therapeutics. In 2017 it landed an FDA de novo clearance for its reSET system, which is focused on substance use disorders. This was shortly followed by the clearance of reSET-O, an opioid use disorder therapy. The company made a deal with Novartis to commercialize the products, but in October  the two broke ties, and Novartis gave commercialization responsibilities back to Pear. 

In April, it took advantage of the FDA's loosening up of regulations for digital psychiatric-disorder devices during the coronavirus crisis and rolled out its new therapeutic aimed at treating schizophrenia. It also landed clearance for Somryst, a prescription digital therapeutic for chronic insomnia, which was the first to be evaluated through the FDA's Digital Health Software Precertification Program.

Happify Health and SilverCloud are two other digital health companies in the mental health space. 

 

ADVERTISEMENT

Optum
 

POPULATION HEALTH

WHO's new anti-tobacco program pairs AI 'virtual health worker' with nicotine replacement treatments >>

The Access Initiative for Quitting Tobacco and will first be piloted in Jordan.

 

TELEHEALTH

Teladoc faces lawsuit over robocalls >>

Plaintiffs allege that the telehealth giant contracted with a third-party telemarketer that violated the Telephone Consumer Protection Act.

 

FUNDING & IPOS

Paige adds $20M to Series B round from Goldman Sachs, Healthcare Venture Partners >>

Paige says the new funds will be used to continue the growth of its platform by creating diagnostic and clinical improvements to patient care.

 

DIGITAL HEALTH

Chelsea Clinton takes on health investing, study finds VR helps ease chronic pain and other digital health briefs >>

Also: Soterix Medical gets green light from FDA to trial its take-home transcranial direct-current stimulation therapy, while MammoScreen gets a 510(k).

 

DIGITAL HEALTH

Doccla and Northampton NHS trust trial virtual wards for vulnerable patients >>

The new project will use wearable technology to enable vulnerable patients at home to be remotely monitored by hospital clinicians.

 

HIMSS TV

COVID-19 ringing in new mobile age >>

Cam Deemer, president of DrFirst, says the pandemic has forced the adoption of telehealth and other technologies that already existed.

 

HIMSS INSIGHTS

COVID-19 and Beyond >>

The latest issue in the HIMSS Insights series focuses on the implications of the coronavirus crisis for healthcare and healthcare digitization. Several months into the crisis at the time of publication, we try to identify major trends coming out of COVID-19 and unmet digital needs that are being unmasked. The second area of focus is digital health technology assessment which is arising in several healthcare systems and remains highly relevant during the pandemic and beyond.

 

ADVERTISEMENT

HIMSS Analytics
 
 

Real-time analytics, during the pandemic and beyond >>

 

PUTTING DATA TO WORK

This month, we look at the lasting lessons from the COVID-19 crisis about how data is exchanged, how it's managed, how it's visualized, how it's put to work informing patient care decisions and population health.

Facebook Twitter LinkedIn

MobiHealthNews & HIMSS Media.
Editorial Inquiries | Advertising | Privacy Policy | Unsubscribe

33 West Monroe Street, Suite 1700, Chicago, IL 60603-5616